Document is current

Article History

Received: 22 October 2024

Accepted: 18 December 2024

First Online: 11 March 2025

Declarations

:

: Not applicable.

: Not applicable.

: ADM participated in the advisory board of the Deutsche Myasthenie Gesellschaft. AM is an advisor, consultant, speaker, and/or investigator and has received research grants (paid to his institution) and honoraria from Alexion AstraZeneca Rare Disease, argenx, Axunio, Grifols, Hormosan, Immunovant, Janssen, Merck, Novartis, Octapharma, Regeneron, Sanofi and UCB. He served as chairman of the medical advisory board of the German Myasthenia Gravis Society. CA received funding for travel, meeting attendance and advisory board participation from Alexion, Momenta, Sanofi, Janssen, argenx and UCB. CP received sponsorship from Novartis and Jazz Pharmaceuticals. EC received public speaking honoraria and compensation for advisory boards and/or consultations fees from UCB, argenx, Alexion, Janssen and Lundbeck. ES received travel grants from UCB, argenx, Roche, Novartis and Merck. ES participated in advisory boards from argenx, Alexion, Biogen, Roche, Novartis and Merck. ES received a research grant from argenx. FP has received research grants from Janssen, Merck KGaA and UCB, and fees for serving on data monitoring committees in clinical trials with Chugai, Lundbeck and Roche, and preparation of expert witness statement for Novartis. FS received travel/accommodation/meeting expenses from Alexion Pharmaceuticals and argenx, received speaking honoraria and honoraria for attendance at advisory boards from Alexion Pharmaceuticals, argenx and UCB pharma. She received research grants from Alexion Pharmaceuticals and Octapharma and grants for administrative support for the German myasthenia gravis registry from the German Myasthenia gravis Society e.V. FV received compensation for travel, meeting attendance, consultation and speaking by Alexion Pharmaceuticals, UCB Pharma, argenx, and Biogen. JV has been involved MG research sponsored by the Princes Beatrix Fonds, Health Holland and consultancies for argenx, Alexion, and NMD Pharma. Reimbursements were received by the LUMC. He is the coinventor on patent applications based on MuSK-related research. The LUMC receives royalties for MuSK antibody assays. JP has received consulting fees from KYomed INNOV. MIL is funded by the NHS (Myasthenia and Related Disorders Service and National Specialised Commissioning Group for Neuromyelitis Optica, UK) and by the University of Oxford, UK. She has been awarded research grants from the UK association for patients with myasthenia (Myaware), Muscular Dystrophy UK and the University of Oxford. She has received speaker honoraria or travel grants from Biogen, Novartis, UCB Pharma, and the Guthy-Jackson Charitable Foundation. She serves on scientific or educational advisory boards for UCB Pharma, argenx, and Horizon Therapeutics (now Amgen Inc.). NEG has received honoraria as a consultant or speaker from argenx, Alexion, UCB, Merck, Roche, Immunovant, Johnson & Johnson, Huma, Denka, Dianthus, Grifols, Amgen, and Takeda. RM has received funding for Travel, Meeting attendance or Advisory Board participation from Alexion, argenx, Biomarin, Catalyst, SANOFI, Regeneron, Merck and UCB. SA has received consulting from UCB pharma, Alexion, argenx and research grant from UCB pharma. SS has received consulting from UCB pharma, Alexion, argenx and research grant from UCB pharma. The other authors (AS, GT, JG, LC, VS, and IM) have declared that no conflict of interest exists.